Ponatinib: Black Box Warning and Drug Interactions

Share this content:
If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.
If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

Chronic myeloid leukemia (CML) is a hematological condition with a large range of treatment options developed over the last decade. Drug development programs predominantly target the BCR-ABL fusion gene resulting from the Philadelphia chromosome translocation. As a tyrosine kinase, the BCR-ABL product is susceptible to tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib.

Each TKI has its own unique properties, indications, and side effects, though the most common adverse events in the TKI family include gastrointestinal side effects, myelosuppression, rash, headache, and peripheral edema. Most patients tolerate TKIs well, with only about 5% to 10% of patients discontinuing the medication due to side effects.1

Some patients, however, will discontinue TKIs due to resistance. Primary resistance is when a TKI does not attain clinical response;  secondary resistance is when a patient initially responds but then relapses. Primary resistance and secondary resistance can occur in up to 25% and 8% to 10% of patients with CML, respectively.2,3

Because of the potential for TKI intolerance and resistance, ponatinib was developed as an oral agent against the mutated BCR-ABL protein, specifically the T315I mutation. Soon after its initial release, ponatinib was removed from the market based on concerns over arterial and venous thromboses, as well as liver toxicity. Ponatinib was eventually re-released, though multiple black box warnings were updated in the prescribing information (PI).

RELATED: TKI Discontinuation and Chronic Myeloid Leukemia

The current PI for ponatinib states that there were arterial occlusions in “at least 35%” of treated patients compared to 6% of patients having venous thromboembolisms.4 These vascular adverse events led to myocardial infarctions, strokes, and peripheral vascular disease.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters